BioSpace News Archive

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the virtual Morgan Stanley 18 th Annual Global Healthcare Conference via webcast on Wednesday, September 16, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 12:30 p.m. Eastern Time. The live webcast

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced that its Board of Directors has promoted John P. Shannon to the position of President and Chief Operating Officer, effective immediately. In his new role, Mr. Shannon will be responsible for

TechnoVax, Inc, a biotechnology developer of novel vaccines and The CUNY School of Medicine at The City College of New York, announce a breakthrough in their collaborative effort to develop a vaccine for COVID-19.

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its second quarter 2020 financial results after market close on Thursday, August 27, 2020. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and

Atrion Corporation announced an increase in its quarterly cash dividend from $1.55 per share to $1.75 per share. Specifically, the Board of Directors declared a quarterly dividend of $1.75 per share on its outstanding shares of Common Stock.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 270,000 shares of Geron common stock as inducements to four newly-hired employees in connection with commencement of employment with the Company.

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage FutureCast: An R&D and Portfolio Review on Thursday, September 10, 2020 from 9:00 a.m. to 11:00 a.m. ET. Sage FutureCast will discuss the Company’s research and development s

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that the Company’s common shares have been approved for listing on The Nasdaq Capital Market (“Nasdaq”). Trading is expected to begin on Monday, August 24, 2020, under the symbol “MDNA” on the Nasdaq. The Corporation will retain its listing on the Toronto Stock Exchange under the symbol “MDNA” a

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information circular (the “Circular”) were approved, including: The election of directors (Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John Wallace and Yung Wu); The re-appointment of Ernst & Young LLP, Chartered Ac

Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS ® (carfilzomib) U.S. prescribing information to include its use in comb